Sort   by:  
 Page size 
UnknownRandomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Not available
S-EPMC4881332 | biostudies-literature
UnknownHealthy Aging Brain Care Monitor, Caregiver Version: Screening for Post-Intensive Care Syndrome.
Not available
S-EPMC9112132 | biostudies-literature
UnknownMolecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.
Not available
S-EPMC6369924 | biostudies-literature
UnknownSafety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Not available
S-EPMC7648353 | biostudies-literature
UnknownOpen-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.
Not available
S-EPMC11295983 | biostudies-literature
UnknownTime Spent Engaging in Health Care Among Patients With Left Ventricular Assist Devices.
Not available
S-EPMC9908068 | biostudies-literature
UnknownPhase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Not available
S-EPMC6362066 | biostudies-literature
TranscriptomicsAnalysis of liver gene expression profile in male mice fed alcoholic (Lieber-Decarli's) diet and calorie-matched control diet for 6 weeks
Microarray analysis showed dysregulation of genes involved in lipid, xenobiotic and glutathione metabolism as well as those involved in mitochondrial function and cell proliferation in the livers of C57BL6 mice fed alcoholic liquid diet for 6 weeks. We analyzed liver RNA from 4 mice fed alcoholic di...
ORGANISM(S): Mus musculus 
2012-12-19 | E-GEOD-30829 | biostudies-arrayexpress
UnknownA phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Not available
S-EPMC5344293 | biostudies-literature
UnknownFirst-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Not available
S-EPMC10264501 | biostudies-literature
Sort   by:  
 Page size